(Q35193326)

English

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 August 2017

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s (English)

1 reference

Europe PubMed Central

7 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Pablo Tebas

4

0 references

3

object named as

Paul E Sax

1 reference

Europe PubMed Central

7 August 2017

1

object named as

Grace A McComsey

1 reference

Europe PubMed Central

7 August 2017

10

object named as

Eric S Daar

1 reference

Europe PubMed Central

7 August 2017

author name string

Douglas Kitch

2

1 reference

Europe PubMed Central

7 August 2017

Camlin Tierney

5

1 reference

Europe PubMed Central

7 August 2017

Nasreen C Jahed

6

1 reference

Europe PubMed Central

7 August 2017

Laurie Myers

7

1 reference

Europe PubMed Central

7 August 2017

Kathleen Melbourne

8

1 reference

Europe PubMed Central

7 August 2017

Belinda Ha

9

1 reference

Europe PubMed Central

7 August 2017

language of work or name

0 references

publication date

1 July 2011

1 reference

Europe PubMed Central

7 August 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

7 August 2017

53

1 reference

Europe PubMed Central

7 August 2017

2

1 reference

Europe PubMed Central

7 August 2017

185-196

1 reference

Europe PubMed Central

7 August 2017

Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

28 July 2018

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

28 July 2018

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

28 July 2018

How much fat loss is needed for lipoatrophy to become clinically evident?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

27 September 2018

Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

27 September 2018

Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

27 September 2018

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

27 September 2018

Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

27 September 2018

Long-Term Body Fat Outcomes in Antiretroviral-Naive Participants Randomized to Nelfinavir or Efavirenz or Both Plus Dual Nucleosides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

27 September 2018

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

27 September 2018

Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

27 September 2018

Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

27 September 2018

Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

27 September 2018

Redefining lipodystrophy syndrome: risks and impact on clinical decision making

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

27 September 2018

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

27 September 2018

Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

27 September 2018

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

27 September 2018

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3165963

27 September 2018

Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR324

21 January 2018

Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically

1 reference

https://pubmed.ncbi.nlm.nih.gov/21690627

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abnormal fat distribution and use of protease inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21690627

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21690627

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21690627

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/21690627

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/CID/CIR324

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35193326&oldid=2023067514"